Ocugen CMO Huma Qamar departs; Mohamed Genead named acting interim CMO

Ocugen, Inc.

Huma Qamar separated from Ocugen as Chief Medical Officer effective May 8, 2026.
Mohamed Genead, M.D., appointed Acting/Interim Chief Medical Officer effective May 8, 2026.
No reason for departure or transition details were disclosed in the filing.

item 5.02item 8.01

Source: SEC EDGAR

accession 0001104659-26-061241

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.